BIOPHYTIS (EPA:ALBPS) - Biophytis shares and BSA trading is suspended pending a new press release
Transparency directive : regulatory news
30/09/2020 08:00
Click here to download pdf version
Press ReleaseBiophytis shares and BSA trading is suspended pending a new press release
Paris (France), Cambridge (Massachusetts, USA), September 30, 2020, 8.00 a.m.
CEST - BIOPHYTIS (Euronext Growth Paris) asked Euronext Paris to suspend the
trading of its shares (ISIN code : FR0012816825-ALBPS) and BSA (ISIN code :
FR0013507290-BPSBS) as from today 30th September 2020, pending the publication
of a new press release.
About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company specialized in the
development of drug candidates to slow down degenerative processes and improve
functional abilities in patients with age-related diseases, including
neuromuscular diseases.
Sarconeos (BIO101), our leading drug candidate, is a small molecule,
administered orally, currently in clinical Phase 2b in sarcopenia (SARA-INT) in
the United States and Europe. A pediatric formulation of Sarconeos (BIO101) is
being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The
company plans to start the clinical development (MYODA) in H2 2020.
Sarconeos (BIO101) is also being developed as a treatment for patients with
COVID-19 related respiratory failure in a Phase 2/3 clinical study (COVA) in
the United States, Europe and Latin America.
The company is based in Paris, France, and Cambridge, Massachusetts. The
company's common shares are listed on the Euronext Growth Paris market (Ticker:
ALBPS -ISIN: FR0012816825). For more information visit www.biophytis.com
Biophytis Contact for Investor Relations
Evelyne Nguyen, CFO
evelyne.nguyen@biophytis.com
Media contact
Citigate Dewe Rogerson
Sylvie Berrebi/ Nathaniel Dahan/ David Dible / Quentin Dussart
biophytis@citigatedewerogerson.com
Tel: +44 (0) 20 7638 9571 / +33 (0)6 59 42 29 35
BIOPHYTIS's latest news
18/04/2024 07:02
18/04/2024 07:00
15/04/2024 07:00
08/04/2024 23:12
08/04/2024 23:10
08/04/2024 23:04
08/04/2024 23:01
08/04/2024 23:00
04/04/2024 23:00
04/04/2024 23:00
Other stories
18/04/2024 23:12
18/04/2024 17:39
19/04/2024 00:07
18/04/2024 14:08
18/04/2024 20:58
18/04/2024 14:23
18/04/2024 01:46
18/04/2024 23:18
18/04/2024 19:33
18/04/2024 14:36
18/04/2024 15:55
18/04/2024 21:25
18/04/2024 19:44
18/04/2024 23:44
18/04/2024 20:36
18/04/2024 19:02
18/04/2024 23:11
18/04/2024 17:44
18/04/2024 15:08
17/04/2024 11:56
18/04/2024 17:33
18/04/2024 12:46
18/04/2024 23:00
18/04/2024 18:13
18/04/2024 15:48
18/04/2024 19:18
19/04/2024 00:10
18/04/2024 23:05
18/04/2024 19:38
18/04/2024 21:56
18/04/2024 07:11
18/04/2024 17:58
18/04/2024 11:30
17/04/2024 09:30
18/04/2024 08:00
18/04/2024 15:22
18/04/2024 12:50
16/04/2024 18:13